Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-021-04017-2
Abstract: The effect of preoperative vedolizumab (VDZ) therapy on postoperative complications in inflammatory bowel disease (IBD) patients is still controversial. This meta-analysis aims to review postoperative complications of IBD patients who preoperatively received VDZ. A meta-analysis… read more here.
Keywords: vdz; postoperative complications; infectious complications; ibd patients ... See more keywords
Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohort
Sign Up to like & getrecommendations! Published in 2024 at "European Journal of Pediatrics"
DOI: 10.1007/s00431-024-05683-4
Abstract: Evidence on serological responses to vaccination in children exposed to ustekinumab (UST) or vedolizumab (VDZ) in utero is lacking. This multicentre prospective study aimed to assess the impact of prenatal exposure to UST or VDZ… read more here.
Keywords: children exposed; vdz; response; vaccination ... See more keywords
MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.
Sign Up to like & getrecommendations! Published in 2021 at "Genomics"
DOI: 10.1016/j.ygeno.2021.04.011
Abstract: Infliximab/adalimumab (IFX/ADA) and vedolizumab (VDZ) are the most widely used biologics in inflammatory bowel diseases. Current models used to predict their efficacies are restricted to either Crohn's disease or ulcerative colitis or to only one… read more here.
Keywords: ifx ada; vdz; inflammatory bowel; bowel diseases ... See more keywords
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
Sign Up to like & getrecommendations! Published in 2023 at "Scandinavian journal of gastroenterology"
DOI: 10.1080/00365521.2023.2176252
Abstract: OBJECTIVE Vedolizumab (VDZ) for subcutaneous (SC) administration has recently become available. We aimed to assess feasibility, safety and clinical outcome when switching from intravenous (IV) to SC VDZ maintenance treatment in a real world cohort… read more here.
Keywords: vdz; disease; maintenance treatment; switching intravenous ... See more keywords
P267 Sequencing of anti-TNF agents and gut-selective anti-lymphocyte trafficking (GSALT) therapy in the treatment of Crohn’s disease (CD)
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.392
Abstract: Anti-TNF agents and GSALT therapy (MAdCAM α4β7 blocker) are available treatment options for patients (pts) with moderate-to-severe CD. There are limited data on the optimal sequencing of these two mechanisms of action (MOAs) from the… read more here.
Keywords: vdz; persistence; anti tnf; treatment ... See more keywords
P290 Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.414
Abstract: Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking monoclonal anti-a4β7-integrin antibody, has showed efficacy in multiple phase 3 clinical trials in patients (pts) with inflammatory bowel disease (IBD). Decreased likelihood of response to adalimumab was previously observed… read more here.
Keywords: vdz; without asa; efficacy; concomitant asa ... See more keywords
P527 Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.649
Abstract: Vedolizumab (VDZ) has demonstrated remission in ulcerative colitis (UC) and Crohn’s disease (CD), but its impact on patient (pt) fatigue is not well understood. Herein we report interim fatigue analysis data from a Belgian registry… read more here.
Keywords: colitis; fatigue; crohn; vdz ... See more keywords
P611 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN’S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjac190.0741
Abstract: Vedolizumab (VDZ) is a gut-selective, anti- lymphocyte trafficking drug inhibiting α4β7-integrin approved for treatment of moderately to severely Crohn's disease (CD) and ulcerative colitis (UC). Medical charts from CD patients were retrospectively reviewed in sites… read more here.
Keywords: anti tnf; vdz; group; treatment ... See more keywords
OP39 Vedolizumab response in ulcerative colitis associates with reduced IgG+ plasma cells and FcγR signaling
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0039
Abstract: Vedolizumab (VDZ) targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC), its mode of action (MOA) remains unclear. Previously, we documented that response to VDZ is associated… read more here.
Keywords: vdz; galt; ulcerative colitis; post vdz ... See more keywords
P510 Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease. The VEDUST-EXIT study
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0640
Abstract: Approximately half of patients with IBD in clinical remission (CR) flare within 12 months of withdrawing anti-TNF therapy. However, the outcomes of vedolizumab (VDZ) or ustekinumab (UST) cessation in terms of CR in routine practice… read more here.
Keywords: relapse; disease; vdz; relapse rates ... See more keywords
P578 CDST (Clinical Decision Support Tool) is predictive of steroid-free clinical remission in patients with Crohn's disease treated with vedolizumab in a specific manner which is mainly driven by the serum level of albumin
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjad212.0708
Abstract: The CDST (Clinical Decision Support Tool) was developed to predict response to vedolizumab in Crohn’s disease to identify a subgroup of super responders (SR). We aimed to 1) confirm that prediction of CDST is specific… read more here.
Keywords: vdz; cdst; w54; cfrem ... See more keywords